Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Ablexis Announces Licensing Agreement with Voyager Therapeutics

Ablexis,LLC
Posted on: 23 Oct 18

Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with Voyager Therapeutics, Inc. (NASDAQ:VYGR). The non-exclusive license grants Voyager rights to use the AlivaMab Mouse for antibody drug discovery and development. Financial terms of the license include an upfront payment, development milestones and a royalty on product sales.

“Ablexis welcomes Voyager Therapeutics to the growing list of leading biopharmaceutical companies using the AlivaMab Mouse platform,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “With access to our industry-leading platform, we are excited to work with the Voyager team to help further their mission to discover and develop gene therapies for patients with severe neurological diseases.”

The AlivaMab Mouse is designed to enable and optimize the efficient discovery and development of the next generation of human therapeutic antibodies. The platform has been validated for antibody drug discovery by Ablexis and partners in various formats including regular antibodies, bispecifics and CAR Ts and for a range of applications including:

  • Sequence diverse panels of mAbs
  • Epitope diverse panels of mAbs
  • Challenging targets such as GPCRs
  • Challenging design goals such as IC50 values of very low picomolar

About Ablexis, LLC

Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has non-exclusively licensed the AlivaMab Mouse technology to multiple companies, including global pharmaceutical companies, public and private biotechnology companies and other entities. Ablexis continues making the AlivaMab Mouse available via non-exclusive licenses. For more information, visit www.ablexis.com. For inquiries about licensing AlivaMab Mouse, contact us at info@ablexis.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181023005025/en/

Business Wire
www.businesswire.com

Last updated on: 23/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.